|
|
|
|
|
|
Sponsors and Collaborators: |
University of Copenhagen Aditech Pharma AB |
Information provided by: | University of Copenhagen |
ClinicalTrials.gov Identifier: | NCT00259233 |
12 obese subjects will receive peripheral administration of placebo and 4 escalating doses of PYY1-36 and another 12 obese subjects will receive peripheral administration of placebo and 4 escalating doses PYY3-36 on 5 different test days within one week. The patients will be tested in a single blinded dose escalating protocol. Measurements of appetite, ad libitum energy intake, blood pressure and blood sampling will be performed during the test day.
Condition | Intervention |
Obesity |
Drug: peripheral Peptide YY administration |
MedlinePlus related topics: | Obesity |
ChemIDplus related topics: | Sodium chloride Peptide YY |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Single Blind, Placebo Control, Crossover Assignment, Efficacy Study |
Official Title: | The Effects of Peripheral Administration of Saline, PYY1-36 and PYY3-36 on ad Libitum Energy Intake and Appetite. |
Ages Eligible for Study: | 20 Years to 50 Years |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | B208, 2 |
First Received: | November 25, 2005 |
Last Updated: | April 20, 2007 |
ClinicalTrials.gov Identifier: | NCT00259233 |
Health Authority: | Denmark: The Danish National Committee on Biomedical Research Ethics |
|
|